0941 GMT - News that Roche's tiragolumab drug candidate didn't meet the primary goal of a late-stage clinical trial in lung cancer doesn't come as a surprise for investors, Bryan Garnier says in a note. The Swiss pharmaceutical company released long-awaited data at final analysis for tiragolumab that showed the overall survival goal wasn't met. This was largely anticipated by the market in light of previous data, Bryan Garnier says. Roche had previously pointed at a limited efficacy in terms of progression-free survival and a miss relative to Merck's Keytruda in a separate arm of the same clinical program, the broker says. Shares fall 1%.(adria.calatayud@wsj.com)
(END) Dow Jones Newswires
November 26, 2024 04:41 ET (09:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。